BRPI1008793A2 - composto, uso de um composto, e, composição farmacêutica - Google Patents
composto, uso de um composto, e, composição farmacêuticaInfo
- Publication number
- BRPI1008793A2 BRPI1008793A2 BRPI1008793A BRPI1008793A BRPI1008793A2 BR PI1008793 A2 BRPI1008793 A2 BR PI1008793A2 BR PI1008793 A BRPI1008793 A BR PI1008793A BR PI1008793 A BRPI1008793 A BR PI1008793A BR PI1008793 A2 BRPI1008793 A2 BR PI1008793A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- compound use
- pharmaceutical
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20864809P | 2009-02-26 | 2009-02-26 | |
| PCT/US2010/024853 WO2010099054A2 (en) | 2009-02-26 | 2010-02-22 | Soluble guanylate cyclase activators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1008793A2 true BRPI1008793A2 (pt) | 2016-03-08 |
Family
ID=42410011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1008793A BRPI1008793A2 (pt) | 2009-02-26 | 2010-02-22 | composto, uso de um composto, e, composição farmacêutica |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8507512B2 (pt) |
| EP (1) | EP2401265B1 (pt) |
| JP (1) | JP5411300B2 (pt) |
| KR (1) | KR20110133034A (pt) |
| CN (1) | CN102414194A (pt) |
| AR (1) | AR075609A1 (pt) |
| AU (1) | AU2010218224B2 (pt) |
| BR (1) | BRPI1008793A2 (pt) |
| CA (1) | CA2753434C (pt) |
| CO (1) | CO6430463A2 (pt) |
| IL (1) | IL214559A0 (pt) |
| MX (1) | MX2011008952A (pt) |
| RU (1) | RU2011138970A (pt) |
| TW (1) | TW201035077A (pt) |
| WO (1) | WO2010099054A2 (pt) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100059952A (ko) * | 2007-09-06 | 2010-06-04 | 머크 샤프 앤드 돔 코포레이션 | 가용성 구아닐레이트 사이클라제 활성제 |
| RU2011138970A (ru) | 2009-02-26 | 2013-04-10 | Мерк Шарп Энд Домэ Корп. | Активаторы растворимой гуанилатциклазы |
| EP2632551B1 (en) | 2010-10-28 | 2016-07-06 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| GB2486631A (en) * | 2010-12-01 | 2012-06-27 | Univ Sheffield | Phenol/quinone boronic acids/esters and method of preparation thereof |
| JP5715713B2 (ja) * | 2011-03-10 | 2015-05-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 可溶性グアニル酸シクラーゼ活性化因子 |
| US8815857B2 (en) | 2011-08-12 | 2014-08-26 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
| EP2594270A3 (en) | 2011-11-18 | 2013-07-31 | BIP Patents | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) |
| EP2863914B1 (en) | 2012-06-20 | 2018-10-03 | Merck Sharp & Dohme Corp. | Pyrazolyl derivatives as syk inhibitors |
| RS59394B1 (sr) | 2012-09-07 | 2019-11-29 | Boehringer Ingelheim Int | Alkoksi pirazoli kao rastvorljivi aktivatori guanilatne ciklaze |
| LT2970243T (lt) | 2013-03-15 | 2020-03-10 | Cyclerion Therapeutics, Inc. | Sgc stimuliatoriai |
| CA2923393A1 (en) * | 2013-09-05 | 2015-03-12 | Glaxosmithkline Intellectual Property Development Limited | Novel soluble guanylate cyclase activators and their use |
| EP3079700B1 (en) | 2013-12-11 | 2020-11-25 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| US9611278B2 (en) | 2013-12-11 | 2017-04-04 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| CN106304835A (zh) | 2013-12-11 | 2017-01-04 | 铁木医药有限公司 | sGC刺激剂 |
| WO2015095515A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Sgc activators for the treatment of glaucoma |
| EP3094327A1 (en) | 2014-01-13 | 2016-11-23 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
| WO2015187470A1 (en) | 2014-06-04 | 2015-12-10 | Merck Sharp & Dohme Corp. | Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators |
| TW201625601A (zh) | 2014-07-02 | 2016-07-16 | 諾華公司 | 噻吩－２－基－吡啶－２－基－１ｈ－吡唑－４－羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
| TW201625584A (zh) * | 2014-07-02 | 2016-07-16 | 諾華公司 | 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
| TW201625586A (zh) | 2014-07-02 | 2016-07-16 | 諾華公司 | 環己烯－１－基－吡啶－２－基－１ｈ－吡唑－４－羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
| EA032972B1 (ru) | 2014-07-22 | 2019-08-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы |
| CN105980373A (zh) * | 2014-09-05 | 2016-09-28 | 葛兰素史密斯克莱知识产权发展有限公司 | 新的可溶性鸟苷酸环化酶活化剂及它们的用途 |
| AU2015317824A1 (en) | 2014-09-17 | 2017-03-23 | Cyclerion Therapeutics, Inc. | Pyrazole derivatives as sGC stimulators |
| AU2015317823A1 (en) | 2014-09-17 | 2017-03-23 | Ironwood Pharmaceuticals, Inc. | sGC stimulators |
| US20170298055A1 (en) | 2014-09-17 | 2017-10-19 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
| MX2017003621A (es) * | 2014-09-19 | 2017-07-14 | Glaxosmithkline Ip Dev Ltd | Nuevos activadores de la guanilato ciclasa soluble y su uso. |
| TW201625635A (zh) | 2014-11-21 | 2016-07-16 | 默沙東藥廠 | 作為可溶性鳥苷酸環化酶活化劑之***并吡基衍生物 |
| US10245264B2 (en) | 2015-05-27 | 2019-04-02 | Merck Sharp & Dohme Corp. | Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators |
| EP3310782B1 (en) | 2015-05-28 | 2021-12-01 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
| EP3782996B1 (en) | 2015-06-15 | 2024-04-10 | GlaxoSmithKline Intellectual Property Development Limited | Nrf2 regulators |
| AU2016280236B2 (en) | 2015-06-15 | 2019-02-07 | Astex Therapeutics Limited | Nrf2 regulators |
| EP3359532A1 (en) | 2015-10-06 | 2018-08-15 | GlaxoSmithKline Intellectual Property Development Limited | Biaryl pyrazoles as nrf2 regulators |
| JP2018529744A (ja) * | 2015-10-06 | 2018-10-11 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｎｒｆ２レギュレーターとしてのアリールシクロヘキシルピラゾール |
| US20180344735A1 (en) | 2015-12-14 | 2018-12-06 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION |
| US10316020B2 (en) * | 2015-12-18 | 2019-06-11 | Novartis Ag | Indane derivatives and the use thereof as soluble guanylate cyclase activators |
| WO2017107052A1 (en) | 2015-12-22 | 2017-06-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase stimulators |
| WO2017197555A1 (en) | 2016-05-16 | 2017-11-23 | Merck Sharp & Dohme Corp. | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators |
| US10925876B2 (en) | 2016-05-18 | 2021-02-23 | Merck Sharp & Dohme Corp. | Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders |
| JP2019524710A (ja) | 2016-07-07 | 2019-09-05 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | Ｓｇｃ刺激剤の固体形態 |
| CA3029374A1 (en) | 2016-07-07 | 2018-01-11 | Ironwood Pharmaceuticals, Inc. | Phosphorus prodrugs of sgc stimulators |
| TWI750218B (zh) | 2016-09-02 | 2021-12-21 | 美商賽克瑞恩醫療公司 | sGC 刺激劑 |
| US11331308B2 (en) | 2016-10-11 | 2022-05-17 | Bayer Pharma Aktiengesellschaft | Combination containing sGC activators and mineralocorticoid receptor antagonists |
| US11690828B2 (en) | 2016-11-08 | 2023-07-04 | Cyclerion Therapeutics, Inc. | Treatment of CNS diseases with sGC stimulators |
| WO2018089330A2 (en) | 2016-11-08 | 2018-05-17 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| US20190381039A1 (en) | 2016-12-13 | 2019-12-19 | Cyclerion Therapeutics, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS |
| US11389449B2 (en) | 2017-09-14 | 2022-07-19 | Cyclerion Therapeutics, Inc. | Treatment of metabolic syndrome with an sGC stimulator |
| WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
| EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
| US11897887B2 (en) | 2017-12-19 | 2024-02-13 | Tisento Therapeutics Inc. | sGC stimulators |
| EP3762389B1 (en) | 2018-03-07 | 2024-02-28 | Tisento Therapeutics Inc. | Crystalline forms of an sgc stimulator |
| US20210052528A1 (en) | 2018-04-30 | 2021-02-25 | Bayer Aktiengesellschaft | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment |
| EA202092680A1 (ru) | 2018-05-15 | 2021-04-13 | Байер Акциенгезельшафт | 1,3-тиазол-2-ил-замещенные бензамиды для лечения заболеваний, ассоциированных с сенситизацией нервных волокон |
| EP3574905A1 (en) | 2018-05-30 | 2019-12-04 | Adverio Pharma GmbH | Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group |
| MX2021000363A (es) | 2018-07-11 | 2021-04-29 | Cyclerion Therapeutics Inc | Uso de estimuladores de la guanilato ciclasa soluble (sgc) para el tratamiento de trastornos mitocondriales. |
| CA3117068A1 (en) | 2018-11-28 | 2020-06-04 | Topadur Pharma Ag | Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof |
| WO2020148379A1 (en) | 2019-01-17 | 2020-07-23 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc) |
| WO2021195403A1 (en) | 2020-03-26 | 2021-09-30 | Cyclerion Therapeutics, Inc. | Deuterated sgc stimulators |
| WO2021202546A1 (en) | 2020-03-31 | 2021-10-07 | Cyclerion Therapeutics, Inc. | Early drug interventions to reduce covid-19 related respiratory distress, need for ventilator assistance and death |
| WO2021245192A1 (en) | 2020-06-04 | 2021-12-09 | Topadur Pharma Ag | Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof |
| JP2024515119A (ja) | 2021-04-20 | 2024-04-04 | ティセント セラピューティクス インコーポレーテッド | ｓＧＣ刺激剤 |
| WO2022225902A1 (en) | 2021-04-20 | 2022-10-27 | Cyclerion Therapeutics, Inc. | Treatment of cns diseases with sgc stimulators |
| WO2022265984A1 (en) | 2021-06-14 | 2022-12-22 | Curtails Llc | Use of nep inhibitors for the treatment of gastrointestinal sphincter disorders |
| WO2023018795A1 (en) | 2021-08-11 | 2023-02-16 | Curtails Llc | Nep inhibitors for the treatment of laminitis |
| WO2023237577A1 (en) | 2022-06-09 | 2023-12-14 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB876526A (en) | 1957-12-24 | 1961-09-06 | Geigy Ag J R | Process for the production of new aminobenzoic acid derivatives and their use in pest control |
| US4845079A (en) | 1985-01-23 | 1989-07-04 | Luly Jay R | Peptidylaminodiols |
| US5066643A (en) | 1985-02-19 | 1991-11-19 | Sandoz Ltd. | Fluorine and chlorine statine or statone containing peptides and method of use |
| US4894437A (en) | 1985-11-15 | 1990-01-16 | The Upjohn Company | Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties |
| US4885292A (en) | 1986-02-03 | 1989-12-05 | E. R. Squibb & Sons, Inc. | N-heterocyclic alcohol renin inhibitors |
| US4980283A (en) | 1987-10-01 | 1990-12-25 | Merck & Co., Inc. | Renin-inhibitory pepstatin phenyl derivatives |
| US5089471A (en) | 1987-10-01 | 1992-02-18 | G. D. Searle & Co. | Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents |
| US5034512A (en) | 1987-10-22 | 1991-07-23 | Warner-Lambert Company | Branched backbone renin inhibitors |
| US5063207A (en) | 1987-10-26 | 1991-11-05 | Warner-Lambert Company | Renin inhibitors, method for using them, and compositions containing them |
| US5055466A (en) | 1987-11-23 | 1991-10-08 | E. R. Squibb & Sons, Inc. | N-morpholino derivatives and their use as anti-hypertensive agents |
| US5036054A (en) | 1988-02-11 | 1991-07-30 | Warner-Lambert Company | Renin inhibitors containing alpha-heteroatom amino acids |
| US5036053A (en) | 1988-05-27 | 1991-07-30 | Warner-Lambert Company | Diol-containing renin inhibitors |
| DE3841520A1 (de) | 1988-12-09 | 1990-06-13 | Hoechst Ag | Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
| US5106835A (en) | 1988-12-27 | 1992-04-21 | American Cyanamid Company | Renin inhibitors |
| US5063208A (en) | 1989-07-26 | 1991-11-05 | Abbott Laboratories | Peptidyl aminodiol renin inhibitors |
| US5098924A (en) | 1989-09-15 | 1992-03-24 | E. R. Squibb & Sons, Inc. | Diol sulfonamide and sulfinyl renin inhibitors |
| US5104869A (en) | 1989-10-11 | 1992-04-14 | American Cyanamid Company | Renin inhibitors |
| US5114937A (en) | 1989-11-28 | 1992-05-19 | Warner-Lambert Company | Renin inhibiting nonpeptides |
| US5095119A (en) | 1990-03-08 | 1992-03-10 | American Home Products Corporation | Renin inhibitors |
| US5064965A (en) | 1990-03-08 | 1991-11-12 | American Home Products Corporation | Renin inhibitors |
| US5075451A (en) | 1990-03-08 | 1991-12-24 | American Home Products Corporation | Pyrrolimidazolones useful as renin inhibitors |
| DE4011361A1 (de) | 1990-04-07 | 1991-10-10 | Bayer Ag | 2-aryl-6-hetarylpyridin-derivate |
| US5071837A (en) | 1990-11-28 | 1991-12-10 | Warner-Lambert Company | Novel renin inhibiting peptides |
| DE19744027A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Substituierte Pyrazolo[3,4-b]pyridine, ihre Herstellung und Verwendung in Arzneimitteln |
| DE19744026A1 (de) * | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| GB9824310D0 (en) * | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| US20010044445A1 (en) * | 1999-04-08 | 2001-11-22 | Bamaung Nwe Y. | Azole inhibitors of cytokine production |
| DE19943636A1 (de) * | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| JP4361736B2 (ja) | 2001-03-15 | 2009-11-11 | ビーエーエスエフ ソシエタス・ヨーロピア | ５−フェニルピリミジン、その製造方法、製造のための中間体および有害な菌類を防除するための使用 |
| DE10149370A1 (de) | 2001-10-06 | 2003-04-10 | Merck Patent Gmbh | Pyrazolderivate |
| WO2004047730A2 (en) | 2002-11-21 | 2004-06-10 | New York Blood Center | Compounds for inhibition of hiv infection by blocking hiv entry |
| AU2004230854A1 (en) | 2003-04-03 | 2004-10-28 | Merck & Co., Inc. | Biaryl substituted pyrazoles as sodium channel blockers |
| WO2006012181A1 (en) * | 2004-06-24 | 2006-02-02 | Ksn Energies, Llc | Electrical impedance tomography to characterize tissue |
| WO2006046593A1 (ja) | 2004-10-27 | 2006-05-04 | Daiichi Sankyo Company, Limited | ２以上の置換基を有するベンゼン化合物 |
| PL1846106T3 (pl) * | 2005-01-31 | 2013-03-29 | Dong Wha Pharm Co Ltd | Kompozycja farmaceutyczna do leczenia nefropatii i zdrowa żywność zawierająca wyciągi z ziół |
| AU2006257647A1 (en) | 2005-06-15 | 2006-12-21 | Pfizer Limited | Substituted arylpyrazoles for use against parasites |
| AU2006257638A1 (en) | 2005-06-15 | 2006-12-21 | Pfizer Limited | Substituted arylpyrazoles |
| NZ564916A (en) * | 2005-06-27 | 2011-03-31 | Exelixis Inc | Imidazole based LXR modulators |
| DE102005050375A1 (de) * | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Tetrazol-Derivate und ihre Verwendung |
| EP2079728B1 (en) | 2006-10-10 | 2013-09-25 | Amgen Inc. | N-aryl pyrazole compounds for use against diabetes |
| DE102007015035A1 (de) * | 2007-03-29 | 2008-10-02 | Bayer Healthcare Ag | Substituierte Dibenzoesäure-Derivate und ihre Verwendung |
| DE102007015034A1 (de) * | 2007-03-29 | 2008-10-02 | Bayer Healthcare Ag | Lactam-substituierte Dicarbonsäuren und ihre Verwendung |
| KR20100059952A (ko) * | 2007-09-06 | 2010-06-04 | 머크 샤프 앤드 돔 코포레이션 | 가용성 구아닐레이트 사이클라제 활성제 |
| WO2009068652A1 (en) | 2007-11-30 | 2009-06-04 | Smithkline Beecham Corporation | 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators |
| UY31507A1 (es) | 2007-12-03 | 2009-07-17 | Derivados de piridina activadores de guanilato ciclasa soluble | |
| CN102056907B (zh) | 2008-04-04 | 2014-12-31 | 武田药品工业株式会社 | 杂环衍生物及其用途 |
| WO2010015653A1 (en) | 2008-08-07 | 2010-02-11 | Smithkline Beecham Corporation | Pyrimidine derivatives as activators of soluble guanylate cyclase |
| WO2010015652A2 (en) | 2008-08-07 | 2010-02-11 | Smithkline Beecham Corporation | Thiazole compounds as activators of soluble guanylate cyclase |
| RU2011138970A (ru) | 2009-02-26 | 2013-04-10 | Мерк Шарп Энд Домэ Корп. | Активаторы растворимой гуанилатциклазы |
| EP2632551B1 (en) | 2010-10-28 | 2016-07-06 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
-
2010
- 2010-02-22 RU RU2011138970/04A patent/RU2011138970A/ru not_active Application Discontinuation
- 2010-02-22 MX MX2011008952A patent/MX2011008952A/es active IP Right Grant
- 2010-02-22 CN CN2010800184490A patent/CN102414194A/zh active Pending
- 2010-02-22 AU AU2010218224A patent/AU2010218224B2/en not_active Ceased
- 2010-02-22 KR KR1020117022295A patent/KR20110133034A/ko not_active Application Discontinuation
- 2010-02-22 BR BRPI1008793A patent/BRPI1008793A2/pt not_active IP Right Cessation
- 2010-02-22 WO PCT/US2010/024853 patent/WO2010099054A2/en active Application Filing
- 2010-02-22 EP EP10705728.3A patent/EP2401265B1/en active Active
- 2010-02-22 CA CA2753434A patent/CA2753434C/en not_active Expired - Fee Related
- 2010-02-22 JP JP2011552075A patent/JP5411300B2/ja not_active Expired - Fee Related
- 2010-02-24 US US12/711,854 patent/US8507512B2/en active Active
- 2010-02-25 AR ARP100100555A patent/AR075609A1/es not_active Application Discontinuation
- 2010-02-25 TW TW099105497A patent/TW201035077A/zh unknown
-
2011
- 2011-08-09 IL IL214559A patent/IL214559A0/en unknown
- 2011-09-12 CO CO11117858A patent/CO6430463A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010099054A3 (en) | 2010-10-21 |
| CA2753434A1 (en) | 2010-09-02 |
| EP2401265B1 (en) | 2016-09-14 |
| US8507512B2 (en) | 2013-08-13 |
| RU2011138970A (ru) | 2013-04-10 |
| US20100216764A1 (en) | 2010-08-26 |
| JP5411300B2 (ja) | 2014-02-12 |
| WO2010099054A2 (en) | 2010-09-02 |
| AR075609A1 (es) | 2011-04-20 |
| KR20110133034A (ko) | 2011-12-09 |
| CN102414194A (zh) | 2012-04-11 |
| TW201035077A (en) | 2010-10-01 |
| MX2011008952A (es) | 2011-09-27 |
| IL214559A0 (en) | 2011-09-27 |
| JP2012519169A (ja) | 2012-08-23 |
| CO6430463A2 (es) | 2012-04-30 |
| AU2010218224B2 (en) | 2013-06-27 |
| CA2753434C (en) | 2014-07-15 |
| EP2401265A2 (en) | 2012-01-04 |
| AU2010218224A1 (en) | 2011-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1008793A2 (pt) | composto, uso de um composto, e, composição farmacêutica | |
| BRPI1016219A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI0919942A2 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
| BRPI0907562A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI0921375A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI1007018A2 (pt) | composto, composição farmacêutica, e , uso de um composto. | |
| BR112013008259A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI1008906A2 (pt) | composto, composição farmacêutica, e, uso de um composto. | |
| BR112013015397A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI0921879A2 (pt) | composto, composição farmacêutica , e, uso de um composto | |
| BRPI0810696A2 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
| BR112014001255A2 (pt) | composto, uso de um composto, combinação, e, composição farmacêutica | |
| BRPI0917579A2 (pt) | composto, composição farmacêutica, métodos, e, uso de um composto | |
| BR112014013760A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BRPI0918360A2 (pt) | composto, composição farmacêutica e usos de um composto | |
| BRPI0810161A2 (pt) | Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto | |
| BR112014005669A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BRPI0906937A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI0915134A2 (pt) | composto, e, uso de um composto | |
| BR112014003567A2 (pt) | composto, uso de um composto, e, composição farmacêutica | |
| BR112012031226A2 (pt) | composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica | |
| BRPI1007186A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI0810019A2 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
| BRPI0919165A2 (pt) | composição farmacêutica,e, uso de um composto | |
| BRPI0915473A2 (pt) | composto, composição farmacêutica, e, uso de um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A E 6A ANUIDADES |
|
| B25A | Requested transfer of rights approved |
Owner name: SCHERING CORPORATION (US) |
|
| B25D | Requested change of name of applicant approved |
Owner name: MERCK SHARP AND DOHME CORP. (US) |
|
| B25G | Requested change of headquarter approved |
Owner name: MERCK SHARP AND DOHME CORP. (US) |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2369 DE 31-05-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |